### Guidelines for Treatment of Malaria in the United States
(Based on drugs currently available for use in the United States – updated May 21, 2018)

**CDC Malaria Hotline:** (770) 488-7788 or (855) 856-4713 toll-free Monday-Friday 9 am to 5 pm EST - (770) 488-7100 after hours, weekends and holidays

<table>
<thead>
<tr>
<th>Clinical Diagnosis/Plasmodium species</th>
<th>Region Infection Acquired</th>
<th>Recommended Drug and Adult Dose</th>
<th>Recommended Drug and Pediatric Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncomplicated malaria/ <em>P. falciparum</em> or Species not identified</td>
<td>Chloroquine-resistant or unknown resistance (All malarious regions except those specified as chloroquine-sensitive listed in the box below.)</td>
<td>A. Atovaquone-proguanil (Malarone™)³,⁴ Adult tab = 250 mg atovaquone/100 mg proguanil 4 adult tabs po qd x 3 days</td>
<td>A. Atovaquone-proguanil (Malarone™)³,⁴ Adult tab = 250 mg atovaquone/100 mg proguanil Peds tab = 62.5 mg atovaquone/25 mg proguanil 5 - 8kg: 2 peds tabs po qd x 3 d 9 - 10kg: 3 peds tabs po qd x 3 d 11 - 20kg: 4 peds tabs po qd x 3 d 21 - 30kg: 2 adult tabs po qd x 3 d 31 - 40kg: 3 adult tabs po qd x 3 d &gt; 40 kg: 4 adult tabs po qd x 3 d</td>
</tr>
<tr>
<td>If “species not identified” is subsequently diagnosed as <em>P. vivax</em> or <em>P. ovale</em>: see <em>P. vivax</em> and <em>P. ovale</em> (below) re. treatment with primaquine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. Artemether-lumefantrine (Coartem™)³,⁴ 1 tablet = 20mg artemether and 120 mg lumefantrine A 3-day treatment schedule with a total of 6 oral doses is recommended for both adult and pediatric patients based on weight. The patient should receive the initial dose, followed by the second dose 8 hours later, then 1 dose po bid for the following 2 days. 5 - &lt;15 kg: 1 tablet per dose 15 - &lt;25 kg: 2 tablets per dose 25 - &lt;35 kg: 3 tablets per dose ≥ 35 kg: 4 tablets per dose</td>
<td>C. Quinine sulfate⁵ plus one of the following: Doxycycline⁶, Tetracycline⁶, or Clindamycin Quinine sulfate: 542 mg base (=650 mg salt) po tid x 3 or 7 days⁷ Doxycycline: 100 mg po bid x 7 days Tetracycline: 250 mg po qid x 7 days Clindamycin: 20 mg base/kg/day po divided tid x 7 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D. Mefloquine (Lariam™ and generics)⁹ 684 mg base (=750 mg salt) po as initial dose, followed by 456 mg base (=500 mg salt) po given 6-12 hours after initial dose Total dose= 1,250 mg salt</td>
<td>D. Mefloquine (Lariam™ and generics)⁹ 13.7 mg base/kg (=15 mg salt/kg) po as initial dose, followed by 9.1 mg base/kg (=10 mg salt/kg) po given 6-12 hours after initial dose Total dose= 25 mg salt/kg</td>
</tr>
</tbody>
</table>

---

1. If a person develops malaria despite taking chemoprophylaxis, that particular medicine should not be used as a part of their treatment regimen. Use one of the other options instead.
2. NOTE: There are 4 options (A, B, C, or D) available for treatment of uncomplicated malaria caused by chloroquine-resistant *P. falciparum*. Options A, B, and C are equally recommended. Because of a higher rate of severe neuropsychiatric reactions seen at treatment doses, we do not recommend option D (mefloquine) unless the other options cannot be used. For option C, because there is more data on the efficacy of quinine in combination with doxycycline or tetracycline, these treatment combinations are generally preferred to quinine in combination with clindamycin.
3. Take with food or whole milk. If patient vomits within 30 minutes of taking a dose, then they should repeat the dose.
4. Not recommended in pregnancy or in infants weighing <5 kg. However, may be used if other treatment options are not available or are not being tolerated, and if the potential benefit is judged to outweigh the potential risks.
5. Can be used in second and third trimesters of pregnancy. Can be used in first trimester of pregnancy if no other drug options are available. Not recommended in infants weighing <5 kg.
6. US manufactured quinine sulfate capsule is in a 324mg dosage; therefore 2 capsules should be sufficient for adult dosing. Pediatric dosing may be difficult due to unavailability of non-capsule forms of quinine.
7. Not recommended in pregnancy or in children <8 years old. However, doxycycline or tetracycline may be used in combination with quinine (as recommended for non-pregnant adults) if other treatment options are not available or are not being tolerated, and the benefit is judged to outweigh the risks.
8. For infections acquired in Southeast Asia, quinine treatment should continue for 7 days. For infections acquired elsewhere, quinine treatment should continue for 3 days.
9. Treatment with mefloquine is not recommended in persons who have acquired infections from Southeast Asia due to drug resistance.
# Guidelines for Treatment of Malaria in the United States

(Based on drugs currently available for use in the United States – updated May 21, 2018)

| Uncomplicated malaria/ Species not identified | Chloroquine-sensitive<sup>10</sup> (Central America west of Panama Canal; Haiti; the Dominican Republic; and most of the Middle East) | Chloroquine phosphate (Aralen™ and generics) 600 mg base (=1,000 mg salt) po immediately, followed by 300 mg base (=500 mg salt) po at 6, 24, and 48 hours Total dose: 1,500 mg base (=2,500 mg salt) OR Hydroxychloroquine (Plaquinil™ and generics) 620 mg base (=800 mg salt) po immediately, followed by 310 mg base (=400 mg salt) po at 6, 24, and 48 hours Total dose: 1,550 mg base (=2,000 mg salt) | Chloroquine phosphate (Aralen™ and generics) 10 mg base/kg po immediately, followed by 5 mg base/kg po at 6, 24, and 48 hours Total dose: 25 mg base/kg OR Hydroxychloroquine (Plaquinil™ and generics) 10 mg base/kg po immediately, followed by 5 mg base/kg po at 6, 24, and 48 hours Total dose: 25 mg base/kg |
| Uncomplicated malaria/ P. malariae or P. knowlesi | All regions<sup>10</sup> | Chloroquine phosphate: Treatment as above OR Hydroxychloroquine: Treatment as above | Chloroquine phosphate: Treatment as above OR Hydroxychloroquine: Treatment as above |
| Uncomplicated malaria/ P. vivax or P. ovale | All regions<sup>10</sup> Note: for suspected chloroquine-resistant P. vivax, see row below | Chloroquine phosphate plus Primaquine phosphate<sup>11,12</sup> Chloroquine phosphate: Treatment as above Primaquine phosphate: 30 mg base po qd x 14 days OR Hydroxychloroquine plus Primaquine phosphate<sup>11,12</sup> Hydroxychloroquine: Treatment as above Primaquine phosphate: 30 mg base po qd x 14 days | Chloroquine phosphate plus Primaquine phosphate<sup>11,12</sup> Chloroquine phosphate: Treatment as above Primaquine: 0.5mg base/kg po qd x 14 days OR Hydroxychloroquine plus Primaquine phosphate<sup>11,12</sup> Hydroxychloroquine: Treatment as above Primaquine phosphate: 0.5mg base/kg po qd x 14 days |
| Uncomplicated malaria/ P. vivax | Chloroquine-resistant<sup>13</sup> (Papua New Guinea and Indonesia) | A. Quinine sulfate plus either Doxycycline<sup>7</sup> or Tetracycline<sup>7</sup> plus Primaquine phosphate<sup>11,12</sup> Quinine sulfate: Treatment as above Doxycycline or Tetracycline: Treatment as above Primaquine phosphate: Treatment as above B. Atovaquone-proguanil plus Primaquine phosphate<sup>11,12</sup> Atovaquone-proguanil: Treatment as above Primaquine phosphate: Treatment as above C. Mefloquine plus Primaquine phosphate<sup>11,12</sup> Mefloquine: Treatment as above Primaquine phosphate: Treatment as above | A. Quinine sulfate plus either Doxycycline<sup>7</sup> or Tetracycline<sup>7</sup> plus Primaquine phosphate<sup>11,12</sup> Quinine sulfate: Treatment as above Doxycycline or Tetracycline: Treatment as above Primaquine phosphate: Treatment as above B. Atovaquone-proguanil plus Primaquine phosphate<sup>11,12</sup> Atovaquone-proguanil: Treatment as above Primaquine phosphate: Treatment as above C. Mefloquine plus Primaquine phosphate<sup>11,12</sup> Mefloquine: Treatment as above Primaquine phosphate: Treatment as above |
| Uncomplicated malaria: alternatives for pregnant women<sup>12</sup> | Chloroquine-sensitive (see sections above for regions with chloroquine-resistant malaria species) | Chloroquine phosphate: Treatment as above OR Hydroxychloroquine: Treatment as above | Chloroquine phosphate: Treatment as above OR Hydroxychloroquine: Treatment as above |
| Chloroquine-resistant (see sections above for regions with chloroquine-resistant malaria species) | Artemether-lumefantrine (Coartem™)<sup>15</sup>: Treatment as above if in second or third trimesters OR for all trimesters: Quinine sulfate plus Clindamycin: Treatment as above OR Mefloquine: Treatment as above | Not applicable | Not applicable |

---

<sup>10</sup> When treating chloroquine-sensitive infections, chloroquine and hydroxychloroquine are recommended options. However, regimens used to treat chloroquine-resistant infections may also be used if available.

<sup>11</sup> Primaquine kills any dormant hypnozoites in the liver, thus prevent relapses of P. vivax and P. ovale infections. Because primaquine can cause hemolytic anemia in G6PD-deficient persons, G6PD screening must occur prior to starting treatment with primaquine. For persons with borderline G6PD deficiency, primaquine may be given 45 mg orally one time per week for 8 weeks; consultation with an expert in infectious disease and/or tropical medicine is advised if this alternative regimen is considered in G6PD-deficient persons.

<sup>12</sup> Primaquine must not be used during pregnancy. Pregnant patients with P. vivax and P. ovale infections should be maintained on chloroquine prophylaxis for the duration of their pregnancy. The chemoprophylactic dose of chloroquine phosphate is 300 mg base (=500 mg salt) orally once per week. After delivery, pregnant patients who do not have G6PD deficiency should be treated with primaquine

<sup>13</sup> NOTE: There are three options (A, B, or C) available for treatment of uncomplicated malaria caused by chloroquine-resistant P. vivax. High treatment failure rates due to chloroquine-resistant P. vivax have been well documented in Papua New Guinea and Indonesia. Rare case reports of chloroquine-resistant P. vivax have also been documented in Burma (Myanmar), India, and Central and South America. Persons acquiring P. vivax infections outside of Papua New Guinea or Indonesia should be started on chloroquine. If the patient does not respond, the treatment should be changed to a chloroquine-resistant P. vivax regimen and CDC should be notified (Malaria Hotline number listed above). For treatment of chloroquine-resistant P. vivax infections, options A, B, and C are equally recommended.
### Guidelines for Treatment of Malaria in the United States

(Based on drugs currently available for use in the United States – updated May 21, 2018)

**Severe malaria**\(^{14,15,16,17}\)

<table>
<thead>
<tr>
<th>All regions</th>
<th></th>
</tr>
</thead>
</table>
| **Quinidine gluconate**\(^{15}\) plus one of the following: **Doxycycline**, **Tetracycline**, or **Clindamycin**  
**Quinidine gluconate**: Dose using actual body weight: 6.25 mg base/kg (=10 mg salt/kg) loading dose IV over 1-2 hrs, then 0.0125 mg base/kg/min (=0.02 mg salt/kg/min) continuous infusion for at least 24 hours. An alternative regimen is 15 mg base/kg (=24 mg salt/kg) loading dose IV infused over 4 hours, followed by 7.5 mg base/kg (=12 mg salt/kg) infused over 4 hours every 8 hours, starting 8 hours after the loading dose (see package insert). Once parasite density <1% and patient can take oral medication, complete treatment with oral quinine, dose as above. Quinidine/quinine course = 7 days in Southeast Asia; = 3 days in Africa or South America.  
**Doxycycline**: Treatment as above. If patient not able to take oral medication, give 100 mg IV every 12 hours and then switch to oral doxycycline (as above) as soon as patient can take oral medication. For IV use, avoid rapid administration. Treatment course = 7 days.  
**Tetracycline**: Treatment as above  
**Clindamycin**: Treatment as above. If patient not able to take oral medication, give 10 mg base/kg loading dose IV followed by 5 mg base/kg IV every 8 hours. Switch to oral clindamycin (oral dose as above) as soon as patient can take oral medication. For IV use, avoid rapid administration. Treatment course = 7 days.  
**Investigational new drug (contact CDC for information):**  
Artesunate followed by one of the following: Atovaquone-proguanil (Malarone™), Doxycycline (Clindamycin in pregnant women), or Mefloquine |  |

---

\(^{15}\) Persons with a positive blood smear OR history of recent possible exposure and no other recognized pathology who have one or more of the following clinical criteria (impaired consciousness/coma, severe normocytic anemia, renal failure, pulmonary edema, acute respiratory distress syndrome, circulatory shock, disseminated intravascular coagulation, spontaneous bleeding, acidosis, hemoglobinuria, jaundice, repeated generalized convulsions, and/or parasitemia of > 5%) are considered to have manifestations of more severe disease. The parasite density can be estimated from the percentage of infected RBCs by examining the thin smear slide under oil immersion magnification where the RBCs are more or less touching (approximately 400 RBCs per field), and should be monitored every 12 hours. Severe malaria is most often caused by *P. falciparum*.  
\(^{16}\) Exchange transfusion is no longer recommended based on a systematic review of the literature and analysis of US malaria surveillance data showing no added benefit in severe malaria.  
\(^{17}\) Pregnant women diagnosed with severe malaria should be treated aggressively with parenteral antimalarial therapy.